Shionogi and Co Ltd

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to...
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards...
  3. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  4. Resolving capping issues in tablet manufacturing Natoli explores the various causes of capping and the methods to prevent it
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Industrial data mastery: navigating the 2025 landscape As industrial manufacturers contend with the ever-increasing volume and variety of operational data, the year ahead promises both complexity and opportunity

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Drug Delivery

Akili and Shionogi sign deal to expand digital medicine to Asia

Treatment for ADHD and autism dosed by an action video game is under review by the US FDA and has already found a distributor for Japan and Taiwan
Media

Positive Phase III results in high-risk patients expected to support FDA review process for Roche’s Xofluza

Following the recent news that Roche has announced positive top-line results from its Phase III trial for influenza drug, Xofluza, Tom Moore, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view
Digital

Shionogi modernises product quality management in the cloud

Pharmaceutical company in Japan unifies product quality management processes across global stakeholders
Research & Development

Egalet terminates collaboration with Shionogi

Gains worldwide rights to Phase ! abuse-deterrent, extended-release hydrocodone product candidate
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

New NCEs focus on cancer and orphan diseases

The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
You need to be a subscriber to read this article.
Click here to find out more.

Japan funds R&D for tropical medicines for poor countries

Japanese drug manufacturers are increasing their efforts to ensure more accessible and effective medicines are brought to the developing world
Research & Development

Egalet to collaborate with Shionogi to develop abuse-deterrent oral hydrocodone opioid product candidates

Will receive upfront and milestone payments plus potential royalties on net sales
Subscribe now